{"id":2602,"date":"2026-08-18T14:00:00","date_gmt":"2026-08-18T18:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2602"},"modified":"2026-08-18T19:31:35","modified_gmt":"2026-08-18T23:31:35","slug":"md-anderson-team-reports-dual-myc-gspt1-degrader-for-blood-cancers","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2602","title":{"rendered":"MD Anderson Team Reports Dual MYC-GSPT1 Degrader for Blood Cancers"},"content":{"rendered":"

Institution:<\/strong> MD Anderson (with Kintor, Oncobio, Columbia) · Event Type:<\/strong> Peer-Reviewed Publication (Blood) · Compound:<\/strong> GT19630 · Mechanism:<\/strong> Cereblon-Dependent Dual MYC\/GSPT1 Degrader · Indications:<\/strong> AML, Burkitt Lymphoma, Multiple Myeloma · Publication Date:<\/strong> August 17, 2026<\/p>\n

\"MD<\/p>\n

Summary<\/h4>\n

A peer-reviewed Blood study reports GT19630, a cereblon-dependent small-molecule degrader that directly recruits both MYC and GSPT1 and disrupts a newly described positive feedforward loop between the proteins. GT19630 produced low-nanomolar cytotoxicity across leukemia and lymphoma models, retained activity in TP53-mutant samples, showed a differential effect between CD34-positive AML blasts and normal hematopoietic progenitors, restored venetoclax sensitivity in resistant AML models and prolonged survival in vivo. The evidence is entirely preclinical; human exposure, safety, dosing, biomarkers and clinical activity are unknown.<\/p>\n

What Happened<\/h4>\n

The investigators showed that MYC promotes GSPT1 transcription while GSPT1 supports accurate termination of MYC translation. GT19630 collapses both sides of this circuit, activates the integrated stress response, suppresses tricarboxylic-acid-cycle and oxidative-phosphorylation programs, and induces apoptosis. Activity was reported in Burkitt lymphoma, acute myeloid leukemia and multiple myeloma models, including therapy-resistant states.<\/p>\n

GT19630 is the parent compound; GT19715 has been described publicly as a salt form in earlier disclosures. Prior conference work reported approximately 1.5 nM MYC degradation potency in HL-60 cells and animal tumor regression at low doses. The new article advances the mechanism and multi-model validation into a peer-reviewed record but does not establish an IND, clinical trial or clinical-development timeline.<\/p>\n

Deep Analysis<\/h4>\n

MYC is a central transcriptional regulator of proliferation, metabolism and protein synthesis but has resisted conventional inhibitor development because it lacks stable drug-like pockets and depends on dynamic protein interactions. GSPT1, also known as eRF3a, is a translation-termination factor. Cereblon-recruiting degraders can eliminate GSPT1, trigger stop-codon readthrough and activate proteotoxic stress. GT19630 proposes a dual mechanism: direct MYC loss plus GSPT1 depletion, potentially deepening pathway collapse in MYC-addicted cells.<\/p>\n

The translational attraction is breadth across genetically heterogeneous hematologic malignancies and retained activity in TP53-mutant or venetoclax-resistant settings. The principal safety concern is equally broad biology. MYC and translation termination are essential in normal proliferating tissues, and apparent ex-vivo or murine selectivity may not predict human marrow, gastrointestinal, reproductive or immune toxicity. Cereblon neo-substrate profiles, SALL4 liability, off-target proteomics and exposure-duration relationships will be decisive.<\/p>\n

Durability and resistance are unresolved. Tumors could reduce cereblon, alter degrader-binding interfaces, amplify anti-apoptotic pathways, remodel drug transport or compensate metabolically. Productive degradation also depends on tissue exposure and ternary-complex geometry. Human PK must achieve sustained tumor degradation without chronic normal-tissue suppression.<\/p>\n

Competitive Displacement<\/h4>\n

GSPT1 molecular glues including clinical-stage agents provide the nearest modality benchmark, while indirect MYC approaches target bromodomain proteins, transcription, translation, metabolism or MYC–MAX association. Dual degradation could outperform single GSPT1 recruitment if MYC loss is direct and pharmacologically separable, but broader substrate activity may narrow the therapeutic window. Displacement would require a reproducible advantage in degradation kinetics, refractory disease models, biomarker-defined patient selection and human tolerability. Patent ownership and development rights appear linked to Kintor and Oncobio affiliations, but the current public record does not establish an exclusive clinical-development plan.<\/p>\n

Company and Product Background<\/h4>\n

The work is led by investigators at MD Anderson with collaborators from Kintor Pharmaceutical, Oncobio Therapeutics, Columbia University and international academic centers. GT19630 is a small-molecule cereblon modulator; GT19715 has been described as its salt form. No clinical trial was identified. AML, Burkitt lymphoma and multiple myeloma can depend on MYC-driven transcriptional and metabolic programs. TP53 mutation and venetoclax resistance define particularly difficult treatment contexts in AML.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n\n
Signal<\/th>\nVerified Evidence<\/th>\nCurrent Limit<\/th>\n<\/tr>\n<\/thead>\n
Mechanism<\/td>\nDirect dual MYC and GSPT1 degradation through cereblon<\/td>\nFull neo-substrate\/off-target profile remains incomplete<\/td>\n<\/tr>\n
Evidence breadth<\/td>\nCell lines, primary samples and multiple in-vivo blood-cancer models<\/td>\nAll evidence remains preclinical<\/td>\n<\/tr>\n
Resistance<\/td>\nActivity in TP53-mutant and venetoclax-resistant AML models<\/td>\nHuman resistance biology untested<\/td>\n<\/tr>\n
Selectivity<\/td>\nGreater effect in CD34-positive AML blasts than normal HSPCs<\/td>\nChronic normal-tissue safety unknown<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Dual degradation creates a differentiated therapeutic window in MYC-addicted, treatment-resistant blood cancers, supported by direct target engagement, multi-model activity, primary-sample effects, resistance reversal and comparative progenitor selectivity. This would be upgraded by IND-enabling safety, broad proteomic selectivity and biomarker-linked responses at tolerable exposures.<\/p>\n

Bear case:<\/strong> The apparent potency mainly reflects combined disruption of essential translation and proliferation machinery and may not separate tumors from normal tissues in humans, given the fundamental roles of MYC and GSPT1 and species-specific cereblon pharmacology. This would be strengthened by narrow exposure margins or indiscriminate proteome loss.<\/p>\n

InSilens Take<\/h4>\n

This is a 4\/5 technology signal with uncertain direction. The paper offers an unusually coherent mechanism for attacking MYC addiction and venetoclax resistance, but potency is not treatment readiness. The most important next evidence is quantitative degradation selectivity, human-relevant toxicology, oral exposure and tissue distribution, validated pharmacodynamic biomarkers, resistance mapping, formal development ownership and first-in-human dose escalation.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 — peer-reviewed validation of a dual degrader for resistant blood cancers. Direction:<\/strong> Uncertain — strong preclinical activity with unresolved human therapeutic window. Confidence in facts:<\/strong> High — peer-reviewed abstract and prior primary disclosures align. Confidence in interpretation:<\/strong> Moderate — clinical translation, IP position and development path are incomplete.<\/p>\n","protected":false},"excerpt":{"rendered":"

A peer-reviewed Blood study reports GT19630, a cereblon-dependent small-molecule degrader that directly recruits both MYC and GSPT1 and disrupts a newly described positive feedforward loop between the proteins. GT19630 produced low-nanomolar cytotoxicity across leukemia…<\/p>\n","protected":false},"author":1,"featured_media":2609,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,384],"class_list":["post-2602","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-md-anderson"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2602"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2602\/revisions"}],"predecessor-version":[{"id":2616,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2602\/revisions\/2616"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2609"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}